Global Cystic Fibrosis Therapeutics Market 2018-2022

嚢胞性繊維症治療薬の世界市場2018-2022:CFTRモジュレーター、粘液溶解薬、膵酵素補充薬、抗感染薬、気管支拡張薬

◆タイトル:Global Cystic Fibrosis Therapeutics Market 2018-2022
◆商品コード:IRTNTR20503
◆調査・発行会社:Technavio (Infiniti Research Ltd.)
◆発行日:2018年1月17日
◆ページ数:111
◆資料形式:PDF / 英語
◆納品方法:Eメール(受注後24時間以内)
◆調査対象地域:グローバル
◆産業分野:医療・バイオ
◆販売価格オプション(消費税別)
Single User(1名利用)USD3,500 ⇒換算¥378,000見積依頼/購入/質問フォーム
Five User(~5名利用)USD4,000 ⇒換算¥432,000見積依頼/購入/質問フォーム
Enterprise License(全社内共有可)USD5,000 ⇒換算¥540,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※商品の納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送いたしますので、請求書発行日より2ヶ月以内に銀行振込にて支払をお願いします。(振込先:三菱東京UFJ銀行/京橋支店/H&Iグローバルリサーチ株式会社)
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※ご購入後、資料に記載の英語表現や単語の意味に関しましては無料でお答えいたします。(但し、対応範囲は弊社で判断)
※弊社H&Iグローバルリサーチ株式会社はTechnavio (Infiniti Research Ltd.)の日本における正規販売代理店です。

【資料の概要】

Technavio社が発行した当調査レポートでは、嚢胞性繊維症治療薬の世界市場について調査・分析し、エグゼクティブサマリー、市場概観、市場概観、業界の構造分析、嚢胞性繊維症治療薬の世界市場規模及び予測、薬剤種類別分析、市場の成長要因、市場の課題、市場動向、競争状況などの情報をお届けいたします。

About Cystic Fibrosis Therapeutics
CF is a genetic disorder that mostly affects the lungs and sometimes other parts of the body such as the liver, pancreas, intestines, and the kidneys. The disease is inherited in an autosomal recessive manner. It is due to mutations caused in both the copies of the gene for the CFTR protein.

Technavio’s analysts forecast the global cystic fibrosis therapeutics market to grow at a CAGR of 17.28% during the period 2018-2022.

[Covered in this report]
The report covers the present scenario and the growth prospects of the global cystic fibrosis therapeutics market for 2018-2022. To calculate the market size, the report presents a detailed picture of the market by way of study, synthesis, and summation of data from multiple sources.

The market is divided into the following segments based on geography:
• Americas
• APAC
• EMEA

Technavio’s report, Global Cystic Fibrosis Therapeutics Market 2018-2022, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.

[Key vendors]
• AbbVie
• Gilead
• F. Hoffmann-La Roche
• Vertex Pharmaceuticals

[Market driver]
• Improved diagnostic technologies
• For a full, detailed list, view our report

[Market challenge]
• Drug discontinuation
• For a full, detailed list, view our report

[Market trend]
• Strategic collaborations
• For a full, detailed list, view our report

[Key questions answered in this report]
• What will the market size be in 2022 and what will the growth rate be?
• What are the key market trends?
• What is driving this market?
• What are the challenges to market growth?
• Who are the key vendors in this market space?

*** You can request one free hour of our analyst’s time when you purchase this market report. Details are provided within the report.

【資料の目次】

Table of Contents
PART 01: EXECUTIVE SUMMARY

PART 02: SCOPE OF THE REPORT

PART 03: RESEARCH METHODOLOGY

PART 04: INTRODUCTION
• Market outline

PART 05: MARKET LANDSCAPE
• Market ecosystem
• Market characteristics
• Market segmentation analysis

PART 06: MARKET SIZING
• Market definition
• Market sizing
• Market size and forecast

PART 07: FIVE FORCES ANALYSIS
• Bargaining power of buyers
• Bargaining power of suppliers
• Threat of new entrants
• Threat of substitutes
• Threat of rivalry
• Market condition

PART 08: MARKET SEGMENTATION BY DRUG CLASS
• Comparison by drug class
• CFTR modulators
• Mucolytics
• PERT
• Anti-infectives
• Bronchodilators
• Market opportunity by drug class

PART 09: CUSTOMER LANDSCAPE

PART 10: REGIONAL LANDSCAPE
• Regional comparison
• CF therapeutics market in Americas
• CF therapeutics market in EMEA
• CF therapeutics market in APAC
• Market opportunity

PART 11: DECISION FRAMEWORK

PART 12: DRIVERS AND CHALLENGES
• Market Drivers
• Market challenges

PART 13: MARKET TRENDS
• Strategic collaborations
• Advances in technology for drug development and delivery

PART 14: VENDOR LANDSCAPE
• Overview
• Landscape disruption
• Competitive scenario

PART 15: VENDOR ANALYSIS
• Vendors covered
• Vendor classification
• Market positioning of vendors
• AbbVie
• Gilead
• F. Hoffmann-La Roche
• Vertex Pharmaceuticals

PART 16: APPENDIX
• List of abbreviations

[List of Exhibits]
Exhibit 01: Autosomal recessive pattern of inheritance in CF
Exhibit 02: Effects of CF on different body parts
Exhibit 03: Most common CFTR mutations
Exhibit 04: Global birth prevalence of CF by 2017
Exhibit 05: Diagnosis and treatment of CF
Exhibit 06: Parent market
Exhibit 07: Market characteristics
Exhibit 08: Market segments
Exhibit 09: Market definition: Inclusions and exclusions checklist
Exhibit 10: Market size
Exhibit 11: Validation techniques employed for market sizing 2017
Exhibit 12: Global CF therapeutics market 2017-2022 ($ millions)
Exhibit 13: Global CF therapeutics market: Year over year growth 2018-2022 (%)
Exhibit 14: Five forces analysis 2017
Exhibit 15: Five forces analysis 2022
Exhibit 16: Bargaining power of buyers
Exhibit 17: Bargaining power of suppliers
Exhibit 18: Threat of new entrants
Exhibit 19: Threat of substitutes
Exhibit 20: Threat of rivalry
Exhibit 21: Market condition: Five forces 2017
Exhibit 22: Global CF therapeutics market by drug class 2017-2022 (% share)
Exhibit 23: Comparison by drug class
Exhibit 24: Global CF therapeutics market by CFTR modulators 2017-2022 ($ millions)
Exhibit 25: KALYDECO description
Exhibit 26: ORKAMBI description
Exhibit 27: Global CF therapeutics market by CFTR modulators: Year over year growth 2018-2022 (%)
Exhibit 28: Global CF therapeutics market by mucolytics 2017-2022 ($ millions)
Exhibit 29: Global CF therapeutics market by mucolytics: Year over year growth 2018-2022 (%)
Exhibit 30: Global CF therapeutics market by PERT 2017-2022 ($ millions)
Exhibit 31: Global CF therapeutics market by PERT: Year over year growth 2018-2022 (%)
Exhibit 32: Global CF therapeutics market by anti-infectives 2017-2022 ($ millions)
Exhibit 33: Global CF therapeutics market by anti-infectives: Year over year growth 2018-2022 (%)
Exhibit 34: Global CF therapeutics market by bronchodilators 2017-2022 ($ millions)
Exhibit 35: Global CF therapeutics market by bronchodilators: Year over year growth 2018-2022 (%)
Exhibit 36: Market opportunity by drug class
Exhibit 37: Customer landscape
Exhibit 38: Global CF therapeutics market by region 2017-2022 (% share)
Exhibit 39: Regional comparison
Exhibit 40: CF therapeutics market in Americas 2017-2022 ($ millions)
Exhibit 41: CF therapeutics market in Americas: Year over year growth 2018-2022 (%)
Exhibit 42: Top three countries in Americas
Exhibit 43: CF therapeutics market in EMEA 2017-2022 ($ millions)
Exhibit 44: CF therapeutics market in EMEA: Year over year growth 2018-2022 (%)
Exhibit 45: Top three countries in EMEA
Exhibit 46: CF therapeutics market in APAC 2017-2022 ($ millions)
Exhibit 47: CF therapeutics market in APAC: Year over year growth 2018-2022 (%)
Exhibit 48: Top three countries in APAC
Exhibit 49: Market opportunity
Exhibit 50: Few drugs with breakthrough therapy designation for CF
Exhibit 51: Few drugs with Orphan Drug Designation for CF
Exhibit 52: Few CF therapeutics discontinued from development
Exhibit 53: Partnerships and collaborations between companies for development of CF therapeutics
Exhibit 54: Vendor landscape
Exhibit 55: Landscape disruption
Exhibit 56: Competitive structure analysis of global CF therapeutics market 2017
Exhibit 57: Vendors covered
Exhibit 58: Vendor classification
Exhibit 59: Market positioning of vendors
Exhibit 60: AbbVie: Overview
Exhibit 61: AbbVie: Business segments
Exhibit 62: AbbVie: Organizational developments
Exhibit 63: AbbVie: Geographic focus
Exhibit 64: AbbVie: Segment focus
Exhibit 65: AbbVie: Key offerings
Exhibit 66: AbbVie: Key customers
Exhibit 67: Gilead: Overview
Exhibit 68: Gilead: Business segments
Exhibit 69: Gilead: Organizational developments
Exhibit 70: Gilead: Geographic focus
Exhibit 71: Gilead: Segment focus
Exhibit 72: Gilead: Key offerings
Exhibit 73: Gilead: Key customers
Exhibit 74: F. Hoffmann-La Roche: Overview
Exhibit 75: F. Hoffmann-La Roche: Business segments
Exhibit 76: F. Hoffmann-La Roche: Organizational developments
Exhibit 77: F. Hoffmann-La Roche: Geographic focus
Exhibit 78: F. Hoffmann-La Roche: Segment focus
Exhibit 79: F. Hoffmann-La Roche: Key offerings
Exhibit 80: F. Hoffmann-La Roche: Key customers
Exhibit 81: Vertex Pharmaceuticals: Overview
Exhibit 82: Vertex Pharmaceuticals: Business segments
Exhibit 83: Vertex Pharmaceuticals: Organizational developments
Exhibit 84: Vertex Pharmaceuticals: Geographic focus
Exhibit 85: Vertex Pharmaceuticals: Segment focus
Exhibit 86: Vertex Pharmaceuticals: Key offerings
Exhibit 87: Vertex Pharmaceuticals: Key customers



【掲載企業】

AbbVie, Gilead, F. Hoffmann-La Roche, and Vertex Pharmaceuticals.

★調査レポート[嚢胞性繊維症治療薬の世界市場2018-2022:CFTRモジュレーター、粘液溶解薬、膵酵素補充薬、抗感染薬、気管支拡張薬] (Global Cystic Fibrosis Therapeutics Market 2018-2022 / IRTNTR20503)販売に関する免責事項
[嚢胞性繊維症治療薬の世界市場2018-2022:CFTRモジュレーター、粘液溶解薬、膵酵素補充薬、抗感染薬、気管支拡張薬] (Global Cystic Fibrosis Therapeutics Market 2018-2022 / IRTNTR20503)についてEメールでお問い合わせ


◆H&Iグローバルリサーチ株式会社のお客様(例)◆